Kezar Life Sciences Inc
NASDAQ:KZR
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.7723
  • TODAY'S CHANGE (%)
    -0.0172 (-2.1786%)
  • Bid / Lots
    0.7700/ 1
  • Ask / Lots
    0.8138/ 8
  • Open / Previous Close
    0.7980 / 0.7895
  • Day Range
    0.7713
    0.7980
  • 52 Week Range
    0.6746
    3.1300
  • Volume
    424,650

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
KZR
Kezar Life Sciences Inc
57.5M
-0.6x
---
KRON
Kronos Bio Inc
60.1M
-0.5x
---
BOLT
Bolt Biotherapeutics Inc
50.3M
-0.5x
---
CIPI
Correlate Energy Corp
48.3M
-3.4x
---
IKNA
Ikena Oncology Inc
55.7M
-0.8x
---
BLRX
BioLine RX Ltd
52.3M
-0.6x
---
As of 2024-05-15

Company Information

Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.

Contact Information

Headquarters
4000 Shoreline Ct Ste 300SOUTH SAN FRANCISCO, CA, United States 94080-2005
Phone
650-822-5600
Fax
302-636-5454

Executives

Independent Chairman of the Board
Graham Cooper
Director
Christopher Kirk
Chief Financial Officer
Marc Belsky
Senior Vice President - Research and Drug Discovery
Neel Anand
Senior Vice President - CMC and Supply Chain
Kieron Wesson

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$57.5M
Revenue (TTM)
$7.0M
Shares Outstanding
72.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.25
EPS
$-1.40
Book Value
$2.58
P/E Ratio
-0.6x
Price/Sales (TTM)
8.2
Price/Cash Flow (TTM)
---
Operating Margin
-1,591.77%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.